Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
2018 · JAMA Oncology · 925 citations
https://doi.org/10.1001/jamaoncol.2017.4771
B
Benjamin Besse
Inserm(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.8K
Papers
55.6K
Citations
100
h-index
498
i10-index
Benjamin Besse is an academic researcher from Inserm. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics & Lung Cancer Research Studies. The author has an h-index of 100, co-authored 1563 publications.
ORCID: 0000-0001-5090-8189Papers by this author
worksLung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
2013 · Journal of Clinical Oncology · 654 citations
https://doi.org/10.1200/jco.2012.45.6095
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
2021 · Nature Cancer · 529 citations
https://doi.org/10.1038/s43018-021-00232-6
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
2015 · Annals of Oncology · 323 citations
https://doi.org/10.1093/annonc/mdv573
Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
2019 · Journal of Thoracic Oncology · 284 citations
https://doi.org/10.1016/j.jtho.2019.07.025
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
2018 · The Lancet Haematology · 269 citations
https://doi.org/10.1016/s2352-3026(18)30175-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat